Related Experiment Videos
Plasma potassium levels in hypertensive patients receiving fixed-combination diuretic therapy
Insights
Fixed-combination diuretics like Moduretic can cause hypokalemia (low potassium) in hypertension patients. Regular monitoring of potassium levels is crucial, even with combination therapy.
Area of Science:
- Nephrology
- Cardiology
- Clinical Pharmacology
Background:
- Hypertension is a common condition requiring long-term management.
- Diuretics are frequently prescribed for hypertension, with fixed-combination therapies aiming for improved efficacy and adherence.
- Hypokalemia is a known side effect of some diuretics, necessitating careful patient monitoring.
Purpose of the Study:
- To investigate the incidence and characteristics of hypokalemia in hypertensive patients receiving a fixed-combination diuretic (hydrochlorothiazide 50 mg/amiloride 5 mg).
- To assess the time course and contributing factors to hypokalemia in this patient group.
Main Methods:
- Observational study of 54 patients at a hospital hypertension clinic.
- Patients were receiving a fixed-combination diuretic (Moduretic: hydrochlorothiazide 50 mg, amiloride 5 mg).
- Plasma potassium levels were monitored regularly to assess incidence and changes.
Main Results:
- A high incidence of hypokalemia (44.4%) was observed.
- The mean plasma potassium level dropped significantly (0.69 mmol/L), with a mean low of 2.81 mmol/L.
- Most potassium drops occurred within 52 weeks, with an average time to hypokalemia of 19.5 weeks.
Conclusions:
- The fixed-combination diuretic (hydrochlorothiazide 50 mg/amiloride 5 mg) showed a high incidence of hypokalemia.
- Regular plasma potassium monitoring is essential for patients on fixed-combination diuretics to prevent complications.
- The efficacy of this specific fixed-combination in preventing hypokalemia is questionable in this clinical setting.
Abstract:
Among 54 patients attending a hospital hypertension clinic and receiving the fixed-combination diuretic Moduretic (hydrochlorothiazide 50 mg, amiloride 5 mg), there was a 44.4% incidence of hypokalaemia. The mean drop in plasma potassium level was 0.69 mmol/L (P less than 0.0001), the mean low level being 2.81 mmol/L. Seventy-four per cent of falls occurred within 52 weeks of the start of therapy, 19.5 weeks being the average period between a normal and a low plasma potassium level. There was no difference in the fall in potassium level between male and female subjects, and beta-blockers were not obviously protective, although there was a statistically significant smaller fall in potassium level in females treated with them. The clinical significance of the unexpected hypokalaemia is uncertain; but even with fixed-combination diuretics, it remains necessary to monitor the plasma potassium level regularly in order to avoid complicating situations. The results of the present study would cast doubt on the efficacy of 5 mg of amiloride with 50 mg of hydrochlorothiazide in fixed-combination form in preventing hypokalaemia in this clinical situation.